EP
FLGT icon

Essential Partners’s Fulgent Genetics FLGT Stock Holding History

Essential Partners’s Portfolio FLGT Stock Details FLGT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.64K Sell
80
-9
-10% -$153 ﹤0.01% 2056
2026
Q1 		$1.42K Buy
+89
New +$1.93K ﹤0.01% 2126

Other funds holding FLGT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $27.8B AUM 46.46% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
DC
Diametric Capital Boston, Massachusetts $948M AUM 47.49% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Essential Partners's FLGT Position: Q2 2026 in Review

Essential Partners reduced its Fulgent Genetics (FLGT) stake by 10% in Q2 2026, selling an estimated $153 and leaving 80 shares worth $1.64K. The position accounts for ﹤0.01% of the portfolio, ranked #2056.

Essential Partners first reported a position in FLGT in Q1 2026 and has held it in 2 quarters since. 142 funds tracked by Wall St. Rank hold FLGT as of Q2 2026.

  • Essential Partners held 80 shares of Fulgent Genetics worth $1.64K as of Q2 2026.
  • Essential Partners sold 9 Fulgent Genetics shares in Q2 2026, an estimated $153.
  • Fulgent Genetics made up ﹤0.01% of Essential Partners's portfolio in Q2 2026, its #2056 holding.
  • Essential Partners first reported a position in Fulgent Genetics in Q1 2026 and has held it in 2 quarters since.
  • 142 funds tracked by Wall St. Rank held Fulgent Genetics as of Q2 2026.

Based on Essential Partners's 13F filing for Q2 2026, filed 10 Aug 2026.